Absci Corp 2025年季度报告

FORM10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedJune30, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number001-40646 ABSCI CORPORATION(Exact name of registrant as specified in its charter) (360)949-1041 Registrant's telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-TYes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitionsof “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ The registrant had outstanding149,522,647shares of $0.0001 par value common stock as of July31, 2025. Table of Contents Part I Financial Information (Unaudited)7Item 1.Unaudited Condensed Consolidated Financial Statements7Unaudited Condensed Consolidated Balance Sheets as of June 30, 2025 andDecember 31, 20247Unaudited Condensed Consolidated Statements of Operations and ComprehensiveLoss for the Three and Six Months Ended June 30, 2025 and 20248Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equityfor the Three and Six Months Ended June 30, 2025 and 20249Unaudited Condensed Consolidated Statements of Cash Flows for the Six MonthsEnded June 30, 2025 and 202411Notes to Unaudited Condensed Consolidated Financial Statements12Item 2.Management’s Discussion and Analysis of Financial Condition and Results ofOperations19Item 3.Quantitative and Qualitative Disclosure About Market Risk29Item 4.Controls and Procedures29Part II Other Information29Item 1.Legal Proceedings30Item 1A.Risk Factors30Item 2.Unregistered Sales of Equity SecuritiesandUse of Proceeds83Item 3.Defaults Upon Senior Securities83Item 4.Mine Safety Disclosures83Item 5.Other Information83Item 6.Exhibits84Signatures85 RISK FACTOR SUMMARY Below is a summary of the principal factors that make an investment in our common stock speculative or risky.This summary does not address all of the risks that we face. Additional discussion of the risks summarized in thisrisk factor summary, and other risks that we face, can be found below in Item 1A. - “Risk Factors” and shouldbe carefully considered, together with other information in this Quarterly Report on Form 10-Q and our otherfilings with the U.S. Securities and Exchange Commission, or the SEC, before making investment decisionsregarding our common stock. •Our plans and expectations regarding the initiation, timing, progress, results, and costs of both of ourinternally developed programs and partnered programs, including current and future preclinical studiesand clinical trials, and the period during which the results of such studies and trials will become available,are subject to a high degree of uncertainty;•Our current business has a limited operating history, which may make it difficult to evaluate our businessand predict our future performance;•We have incurred significant losses since inception, we expect to incur losses in the future and we maynot be able to generate sufficient revenue to achieve and maintain profitability;•We will need to raise additional capital to fund our operations, including the advancement of internallydeveloped programs, and improve our Integrated Drug Creation platform. If we are unable to raiseadditional capital on terms acceptable to us or at all, we may not be able to compete successfully, whichwould harm our business, operations, and financial condition;•Biologic drug development is inherently uncertain, and it is possible that our technology may notsucceed in discovering appropriate molecules. Even if we do succeed, it is possible that none of theproduct candidates created using our Integrated Drug Creation platform that we are developinginternally or that are further developed by our partners will achieve development or regulatorymi